The objectives will be to assess the safety, determine the pharmacokinetic profile of AZP-531 also to provide preliminary data on AZP-531 metabolic effects, on glycemia particularly. This double-blind, placebo-controlled trial will be carried out in three parts: an individual ascending dose study in healthy volunteers, a 14-day multiple ascending dose research in obese or obese subjects and a 14-time multiple ascending dose research in type 2 diabetic patients. Up to 112 sufferers and healthy volunteers will be signed up for the trial. They’ll allow initiation of clinical development in other metabolic indications also, like the Prader Willi syndrome and some ischemia-related cardiovascular indications.‘Restoring or improving sight could make a huge effect on how people live their lives, which is why Abbott is constantly investing in the study and development of advanced treatments to help people find their very best,’ said Murthy Simhambhatla, senior vice president, Medical Optics, Abbott. ‘We are very happy to offer the brand-new TECNIS Multifocal IOLs for those who have cataracts who wish a complete range of vision without having to use eyeglasses, and who also wish high-quality eyesight at a particular distance that is suitable for their life style.’ An IOL can be an artificial lens put into a person's eye to restore vision after a cataract provides been removed.